---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-009385"
form_type: "8-K"
ticker: "ZIVO"
cik: "0001101026"
company_name: "Zivo Bioscience, Inc."
filed_at: "2022-07-07T23:59:59+00:00"
generated_at: "2026-06-24T18:59:16.463313+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Zivo Bioscience adopts staggered board, eliminates shareholder written consent

## Summary
- Board approved Second Amended and Restated Bylaws effective June 30, 2022.
- Creates three-class staggered board; only one class elected per annual meeting after initial election.
- Eliminates stockholder ability to take action by written consent.
- Only the Board may appoint directors to fill vacancies or change the number of directors.
- Adds modernizing provisions for electronic meetings and access to corporate records.

## SEC filing metadata
- accession: 0001654954-22-009385
- form_type: 8-K
- ticker: ZIVO
- cik: 0001101026
- company_name: Zivo Bioscience, Inc.
- filed_at: 2022-07-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1101026/000165495422009385/0001654954-22-009385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1101026/000165495422009385/zivo_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-009385
- JSON: https://secwatch.observer/filing/0001654954-22-009385.json
- Plain text: https://secwatch.observer/filing/0001654954-22-009385.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.